The efficacy of the PAP-loaded-DC-based vaccines is an example, patient immunization with dendritic cells modified to express PAP fused to granulocyte-macrophage colony stimulating factor (GM-CSF), to promote DC survival and proliferation, is able to overcome immune tolerance and generate a proper immune response against prostatic cancer (28). Here, CSF2 is linked to prostate carcinoma.